Allogenic B7-H3 CAR-γδT cell(QH104)

Phase 2Biologic

DDushu Lake Hospital Affiliated to Soochow University

Allogenic B7-H3 CAR-γδT cell(QH104) is one of 2 biologic programs targeting Brain Glioma. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Brain GliomaRecruiting

Brain GliomaPhase 2

Recruiting

Competition

Competitive Landscape

1 competitor in Brain Glioma

#DrugCompanyPhaseTrials

Avastin

Roche

Preclinical

—2

Allogenic B7-H3 CAR-γδT cell(QH104)

DDushu Lake Hospital Affiliated to Soochow University

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

Phase 1/2Recruiting

Brain Glioma

NCT06018363

Clinical

Trials by Indication[1]

Brain Glioma1 trial

Clinical Study on the Treatment of Malignant Brain Glioma by QH104 Cell Injection

Recruiting·—·Phase 1/2·NCT06018363·25 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Allogenic B7-H3 CAR-γδT cell(QH104). U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Allogenic B7-H3 CAR-γδT cell(QH104) compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Allogenic B7-H3 CAR-γδT cell(QH104). EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Dushu Lake Hospital Affiliated to Soochow University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 2[1]
Company: DDushu Lake Hospital Affiliated to Soochow University

Allogenic B7-H3 CAR-γδT cell(QH104)

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Trials by Indication[1]

Brain Glioma1 trial

References

Drug Info

Quick Facts

Related News